Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome.
Picó, María Dolores; Sánchez-Heras, Ana Beatriz; Castillejo, Adela; Giner-Calabuig, Mar; Alustiza, Miren; Sánchez, Ariadna; Moreira, Leticia; Pellise, María; Castells, Antoni; Llort, Gemma; Yagüe, Carmen; Ramon Y Cajal, Teresa; Gisbert-Beamud, Alexandra; Cubiella Fernández, Joaquín; Rivas Moral, Laura; Herraiz, Maite; Garau, Catalina; Salces, Inmaculada; Carrillo-Palau, Marta; Bujanda, Luis; López-Fernández, Adriá; Alvarez-Urturi, Cristina; López, María Jesús; Alenda, Cristina; Zapater, Pedro; Lacueva, Francisco Javier; Balaguer, Francesc; Soto, Jose-Luis; Murcia, Óscar; Jover, Rodrigo
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2020Título de revista
Cancers (Basel)
Tipo de contenido
Journal Article
Resumen
Lynch syndrome (LS) is a common cause of hereditary colorectal cancer (CRC). Some CRC patients develop mismatch repair deficiency without germline pathogenic mutation, known as Lynch-like syndrome (LLS). We compared the risk of CRC in first-degree relatives (FDRs) in LLS and LS patients. LLS was diagnosed when tumors showed immunohistochemical loss of MSH2, MSH6, and PMS2; or loss of MLH1 with BRAF wild type; and/or no MLH1 methylation and absence of pathogenic mutation in these genes. CRC and other LS-related neoplasms were followed in patients diagnosed with LS and LLS and among their FDRs. Standardized incidence ratios (SIRs) were calculated for CRC and other neoplasms associated with LS among FDRs of LS and LLS patients. In total, 205 LS (1205 FDRs) and 131 LLS families (698 FDRs) had complete pedigrees. FDRs of patients with LLS had a high incidence of CRC (SIR, 2.08; 95% confidence interval (CI), 1.56-2.71), which was significantly lower than that in FDRs of patients with LS (SIR, 4.25; 95% CI, 3.67-4.90; p < 0.001). The risk of developing other neoplasms associated with LS also increased among FDR of LLS patients (SIR, 2.04; 95% CI, 1.44-2.80) but was lower than that among FDR of patients with LS (SIR, 5.01, 95% CI, 4.26-5.84; p < 0.001). FDRs with LLS have an increased risk of developing CRC as well as LS-related neoplasms, although this risk is lower than that of families with LS. Thus, their management should take into account this increased risk.
![](/xmlui/themes/Mirage2//images/final_lines.png)